Demographic characteristics, comorbidities, clinical manifestations such as hypoxia and laboratory abnormalities including changes in blood cell counts, increased levels of acute phase proteins (i.e. CRP) and cell damage markers (i.e. LDH) are associated with severity and outcome in COVID-19. This evidence concerns the gene PROS1 and COVID-19.